Elispot and Fluorospot Assay Market

Market Synopsis:

Global Elispot and Fluorospot Assay market is valued at USD 298.51 Million in 2022 and is projected to attain a value of USD 728.59 Million by 2030 at a CAGR of 11.80% during the forecast period, 2022–2028. The rising global incidence of chronic diseases, increased vaccine development to address the challenge of antibiotic resistance, and technological developments in ELISpot and FluoroSpot test kits and analyzers are all driving growth in this market. Availability of alternative detection technologies, on the other hand, is likely to hamper market growth during the forecast period.

The expanding vaccine research to combat the drug-resistant strains problem, the growing global prevalence of chronic illnesses, and technological developments in ELISpot and FluoroSpot analyzers and assay kits are all expected to boost the market growth for ELISpot and FluoroSpot test. ELISpot is a critical step in the development of vaccines for a variety of diseases, including AIDS, TB, HIV, malaria, cancer, and influenza. The ELISpot test is one of the most extensively used immunoassays in vaccine evaluations in clinical trials. The better sensitivity of the sample, statistical read-out, and convenience of use in both mass screening and individual testing contributed to this reputation.

Increased Incidence of Chronic Diseases

Greater awareness of the importance of early diagnosis of chronic diseases, as well as increased use of the FluoroSpot assay, all contribute to the expansion of the ELISpot and FluoroSpot assay markets. Furthermore, the potential for ELISpot and FluoroSpot assay market growth in emerging nations is bolstered by the increase in healthcare expenditure. However, rising costs and a lack of high-quality detection reagents, as well as the fact that the ELISpot and FluoroSpot assays are inaccessible to underdeveloped nations, are obstacles that could stymie market expansion. The hurdles that can stymie market expansion include operational barriers encountered while executing diagnostic tests, variations in the material used, and market player competition.

‹›

Report Coverage & Deliverables

PDF report & online dashboard will help you understand:

• Real-Time Data Updates:
• Competitor Benchmarking
• Market Trends Heatmap
• Custom Research Queries
• Market Sentiment Analysis
• Demographic and Geographic Insights

Book Demo

Get Access Now

High Cost of Equipment Used in Elispot and Fluorospot Assay

The instruments needed to conduct genotyping tests are quite expensive, and their installation necessitates a significant capital expenditure. Elispot and Fluorospot Assay instruments have a lot of advanced features and functions, hence they're expensive. Pharmaceutical businesses and research labs demand a large number of these systems, necessitating large expenditures in many, high-cost genotyping devices. The entire cost of ownership of these instruments rises as a result of maintenance costs and various other indirect charges, such as sample and labor costs. As a result, advanced research facilities such as NGS technology cannot be installed or expanded in academic and research institutes in developing countries across Asia, the Middle East, and Africa.

The Elispot and Fluorospot Assay market scope can be tabulated as below:

Market Segmentation:

On the basis of Product Type, the global Elispot and Fluorospot Assay market is segmented into Assay Kits, Analyzers, Supplementary or Ancillary Products. Based on End User into Hospitals & Clinical labs, Bio-pharmaceutical Company, and Research Institutes. Based on region, the Elispot and Fluorospot Assay market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

North America to Continue Dominating the Elispot and Fluorospot Assay Market

During the projected period, North America is expected to dominate the worldwide Elispot and Fluorospot Assay market, followed by Europe. Increased adoption of technologically advanced Elispot and Fluorospot Assay products, high healthcare expenditures, advanced healthcare infrastructure, highly developed healthcare systems in the US and Canada, a large number of Elispot and Fluorospot Assay-based R&D projects, and the presence of a large number of leading Elispot and Fluorospot Assay manufacturers in the region, as well as increased demand for genotyping products from pharmaceutical companies and rising government investments, by government bodies, are responsible for the large share of the North American Elispot and Fluorospot Assay market.

Key Players:

Key participants operating in the Elispot and Fluorospot Assay market is: Oxford Immunotec USA Inc. (US), BD (US), R&D Systems Inc. (US), Mabtech (Sweden), Thermo Fischer Scientific (US), Covalab Inc. (US), CellCarta (Canada), Oxford BioSystems (UK), Autoimmun Diagnostika GMBH (Germany), Diaclone SAS (France), Abcam plc (UK), Covance Inc. (US), Cellular Technology Ltd (US), U-CyTech (Netherlands), Bio-Techne (US), Mikrogen GMBH (Germany).

The Elispot and Fluorospot Assay market is segmented as follows: